Regeneus: Granted U.S. patent for Progenza
- Regenerative medicine company Regeneus has granted a U.S. patent for its Progenza stem cell treatment
- This new patent covers the treatment of inflammatory conditions using stem cells
- These include inflammatory conditions caused by a wide range of conditions such as arthritis, heart disease
- Progenza is the company’s leading cell therapy technology, which uses stem cells from human connective tissue
- It also works by reducing inflammation and promoting healing and repair in the damaged or diseased tissue
- Then Regeneus shares are up 6.15 per cent on the market and currently trading for 6.9 cents each